Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Endometrial Cancer Recurrent 1 Breast Neoplasms 1 Advanced Cancers 1 Adenocarcinoma of Lung 1 ALK or ROS1-positive NSCLC 1

Interventions

Trastuzumab 78 Capecitabine 59 Cyclophosphamide 54 Paclitaxel 52 Docetaxel 50 Letrozole 44 Fulvestrant 43 Lapatinib 34 Doxorubicin 31 Carboplatin 31 Vinorelbine 30 Bevacizumab 29 Anastrozole 28 pembrolizumab 26 exemestane 24 Tamoxifen 23 Gemcitabine 22 Radiotherapy 21 Albumin-Bound Paclitaxel 19 Taxes 17 Everolimus 17 Epirubicin 15 pertuzumab 13 Ado-Trastuzumab Emtansine 13 130-nm albumin-bound paclitaxel 13 palbociclib 12 Magnetic Resonance Spectroscopy 12 liposomal doxorubicin 11 atezolizumab 11 Filgrastim 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × Crizotinib × Clear all

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡